EMA en­dors­es Teva's mi­graine drug; Dis­as­ter prone CTI Bio­Phar­ma re­scinds EU ap­pli­ca­tion for pa­cri­tinib

7 years ago
News Briefing

Richard Pas­coe takes the helm at His­to­gen; Lon­za COO steps up at CEO Richard Ridinger re­tires

7 years ago
Peer Review

Play­ing hard­ball, Bris­tol-My­ers bought out a bat­tered Cel­gene with last-minute terms sweet­ened in its own fa­vor

7 years ago
Deals

With a deep­er dis­count in place, NICE now ready to en­dorse use of No­var­tis' Kym­ri­ah in adult lym­phoma pa­tients

7 years ago
R&D

MPs threat­en to hi­jack Ver­tex’s IP for its cys­tic fi­bro­sis drugs in a long-run­ning stand­off over price

7 years ago
Pharma

No­vo bets on swift FDA re­view for oral di­a­betes drug semaglu­tide

7 years ago
Pharma

An up­date on the End­points busi­ness mod­el — and how your com­pa­ny can di­rect­ly sup­port it

7 years ago
Publisher's note

Trump ad­min­is­tra­tion pro­pos­es new rules that strip away many of the re­bate deals be­tween phar­ma and PBMs, push­ing ...

7 years ago
Pharma

Buzzy an­ti-ag­ing biotech Cal­i­co re­cruits Am­gen vet for a top re­search post

7 years ago
People

FDA stiff-arms Aveo on ti­vo, again; Sunovion Parkin­son's drug re­ject­ed

7 years ago
News Briefing

Alex­ion lines up a $60M op­tion to buy Fortress-in­cu­bat­ed biotech fo­cused on a lu­cra­tive rare blood dis­ease

7 years ago
Pharma

‘Can we stop that work, can we de­lay that work?’ Bris­tol-My­ers’ top ex­ecs out­line their game plan for ab­sorb­ing ...

7 years ago
Deals

Their lead drug failed both main goals in key study, but Or­p­hazyme plans to pitch sub­group analy­ses to reg­u­la­tors

7 years ago
R&D

J&J snags rights to a gene ther­a­py port­fo­lio from lit­tle MeiraGTx, a spin­off from Sam Wak­sal’s Kad­mon

7 years ago
Pharma
Cell/Gene Tx

With US gov­ern­ment shut­down over, Gos­samer re­verts to tra­di­tion­al IPO plan

7 years ago
Financing

FDA bless­es Mer­ck’s PhI­II ef­fort to top­ple a mega-block­buster — but there’s al­so a lit­tle biotech in this game

7 years ago
Pharma

Af­ter a years-long re­prieve, GSK is about to see My­lan’s gener­ic carve in­to its mega-block­buster Ad­vair fran­chise

7 years ago
R&D
Pharma

That biotech uni­corn you (pick love or hate) just spot­light­ed some in­trigu­ing mouse (yes) da­ta on a triple mR­NA ...

7 years ago
R&D
Discovery

No­var­tis lays out block­buster launch­es for 2018-2020, with sur­pris­ing in­clu­sion of Kym­ri­ah

7 years ago
R&D

Pro­to­cols: No­var­tis CEO is still map­ping out San­doz's fu­ture; But Swiss gi­ant is gung ho on all things dig­i­tal

7 years ago
News Briefing

J&J scores an­oth­er PhI­II win for Er­lea­da as it con­tin­ues to build a block­buster fran­chise

7 years ago
R&D

Path to the top: What kind of ex­pe­ri­ence does it take to get tapped for the helm of a biotech?

7 years ago
People
In Focus

Hop­ing to brake a slow crash, Aduro's Stephen Isaacs hits the re­set but­ton, ax­ing staff in re­or­ga­ni­za­tion

7 years ago
People
R&D

Po­laris’ Amir Nashat pulls to­geth­er a $60M launch round to back the birth of a new biotech build­ing a drug ...

7 years ago
Financing
Startups
First page Previous page 963964965966967968969 Next page Last page
A service from the Financial Times